Vutrisiran治疗与心血管磁共振评估的心脏参数及淀粉样负荷变化
该研究为HELIOS-B试验的回顾性事后分析,纳入43例ATTR-CM患者,其中21例接受vutrisiran治疗。心血管磁共振显示,vutrisiran与双心室射血分数和每搏输出量改善、左心室质量和细胞外容积(ECV)降低相关;36个月时vutrisiran组淀粉样消退比例高于安慰剂组,进展比例更低。
要点
- Vutrisiran与双心室射血分数和每搏输出量显著改善相关。
- Vutrisiran与左心室质量和ECV显著降低相关。
- 36个月时vutrisiran组淀粉样消退比例高于安慰剂组,进展比例更低。
核心结论
- 在该ATTR-CM队列中,vutrisiran治疗与心脏结构、功能及淀粉样负荷相关参数的方向性有利变化相关。
研究设计与样本
- 该研究为英国HELIOS-B试验的回顾性事后分析,单中心于英国国家淀粉样变性中心进行。
- 共43例患者接受基线CMR(21例vutrisiran,22例安慰剂),平均(SD)年龄75.0(5.7)岁,男性41例(95.3%)。
- 分别有39例、26例和17例患者完成1年、2年和3年CMR随访。
- 基线参数组间可比,无患者接受背景tafamidis治疗,分析对治疗分配设盲。
- 采用混合模型分析评估治疗效应,并进行末次观测值结转的敏感性分析。
主要发现
- Vutrisiran与左心室射血分数最小二乘均值差异19.18%(95%CI 11.76%-26.60%,P<.001)相关。
- Vutrisiran与右心室射血分数最小二乘均值差异16.28%(95%CI 9.58%-22.97%,P<.001)相关。
- Vutrisiran与左心室每搏输出量差异27.82 mL(95%CI 13.40-42.23 mL,P<.001)和右心室每搏输出量差异23.69 mL(95%CI 8.06-39.32 mL,P=.003)相关。
- Vutrisiran与左心室质量降低-23.58 g(95%CI -38.78至-8.39 g,P=.002)和ECV降低-6.56%(95%CI -10.10%至-3.01%,P<.001)相关。
- 36个月时,vutrisiran组9例中2例(22%)出现淀粉样消退,安慰剂组无患者消退;安慰剂组8例中5例(63%)进展,vutrisiran组9例中1例(11%)进展。
关键数值与推荐
- 淀粉样消退定义为ECV绝对降低≥5%,进展定义为ECV绝对增加≥5%。
临床怎么用
- 对于ATTR-CM患者,vutrisiran治疗可能带来心脏结构、功能及淀粉样负荷的有利变化,支持其疾病修饰作用。
局限性
- 本研究为单中心回顾性事后分析,样本量小(基线43例,3年随访仅17例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by extracellular myocardial ATTR amyloid infiltration. Vutrisiran, an RNA interference therapeutic that suppresses hepatic TTR production, met its primary end point in the HELIOS-B (A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy) trial. Multiparametric cardiovascular magnetic resonance (CMR) imaging provides high-fidelity structural and functional assessment, including tissue characterization metrics, namely extracellular volume (ECV) mapping, that can track cardiac amyloid load. OBJECTIVE: To analyze the association between treatment with vutrisiran and changes in cardiac structure, function, and amyloid burden by CMR imaging. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective post hoc analysis of CMR data from participants in the UK HELIOS-B trial. This was a single-center study conducted at the UK National Amyloidosis Centre (NAC). The study population comprised participants from the HELIOS-B trial at the NAC who underwent CMR imaging at baseline and 1-, 2-, and 3-year time points as part of routine clinical care. Study data were analyzed March to April 2025. EXPOSURE: CMR imaging during the HELIOS-B trial between April 2020 and August 2024. MAIN OUTCOMES AND MEASURES: CMR parameters of cardiac structure, volumetrics, function, and amyloid burden were assessed. Amyloid regression and progression were defined as absolute reductions and increases in ECV of 5% or greater, respectively. Analysis was blinded to treatment allocation. Changes in CMR parameters between baseline and follow-up were evaluated; a mixed-model analysis was used to assess treatment effect. Sensitivity analyses were conducted using the last observation carried forward. RESULTS: A total of 43 patients (mean [SD] age, 75.0 [5.7] years, 41 male [95.3%]) underwent baseline CMR imaging (21 [48.8%] received vutrisiran; 22 [51.2%] received placebo). Thirty-nine patients (21 received vutrisiran, 18 received placebo), 26 (14 received vutrisiran, 12 received placebo), and 17 (9 received vutrisiran, 8 received placebo) underwent 1-, 2-, and 3-year CMR imaging, respectively. Baseline parameters were comparable between groups. No patients received background tafamidis. Treatment with vutrisiran was associated with statistically significant and directionally favorable changes in biventricular ejection fractions (left ventricular ejection fraction least-squares mean difference, 19.18%; 95% CI, 11.76%-26.60%; P < .001; right ventricular ejection fraction, 16.28%; 95% CI, 9.58%-22.97%; P < .001) and stroke volumes (left ventricular stroke volume, 27.82 mL; 95% CI, 13.40-42.23 mL; P < .001; right ventricular stroke volume, 23.69 mL; 95% CI, 8.06-39.32 mL; P = .003), as well as reductions in left ventricular mass (-23.58 g; 95% CI, -38.78 to -8.39 g; P = .002) and ECV (-6.56%; 95% CI, -10.10% to -3.01%; P < .001). At 36 months, amyloid regression was observed in 2 of 9 patients (22%) taking vutrisiran, and no patients receiving placebo experienced regression. Conversely, 5 of 8 patients (63%) receiving placebo demonstrated progression vs 1 of 9 patients (11%) taking vutrisiran. CONCLUSIONS AND RELEVANCE: Results of this selected ATTR-CM cohort study show that treatment with vutrisiran was associated with favorable changes in parameters relating to cardiac structure, function, and amyloid burden.
引用
- Razvi Y, Sheikh A, Patel RK, et al. Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI. JAMA Cardiol. 2026. PMID: 42584913. doi:10.1001/jamacardio.2026.2812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。